- ETST finalizes agreement with Groupe Opmedic Inc. and its Procrea Fertility Laboratories for lab services to detect sexually transmitted infections (STIs) in women using Hygee
- ETST is in talks with an organic CBD grower and processor for it to provide an exclusive business/supply agreement that will give ETST a consistent industrial hemp source
- Company’s pipeline includes several CBD-based pharmaceutical formulas; ETST expects that its pure hemp oil and new formulas will eventually be sold globally
Earth Science Tech, Inc. (OTCQB: ETST) has advanced on two fronts with its goals of further penetrating the CBD market and medical testing device field to detect STIs in women. Both could result in revenue growth for the company and a larger role in both of these markets.
For Hygee, it has reached agreement with Groupe Opmedic Inc. and its Procrea Fertility Laboratories to offer its lab services for the detection of STIs in women who use Hygee. ETST has already proven Hygee’s ability to detect chlamydia, and the company is now working to validate similar results for gonorrhea. Additionally, the company anticipates testing for other STIs and non-STI infections that will make the device even more important (http://ibn.fm/4kIrP).
“We are excited to be working with a partner that has the same vision as we do,” Dr. Michel Aubé, CEO and CSO of ETST, stated in a news release. “We are concerned for the health of all women and the babies they carry when pregnant. The CT test is so essential for infant’s health that the World Health Organization (WHO) encourages all sexually active women between the ages of 15 and 25 to be tested once a year.” Procrea Fertility offers an advanced range of lab testing of cervical cells.
On the CBD front, ETST is in discussions with an organic grower and processor for an exclusive business/supply relationship that offers the company its outdoor organic industrial hemp plants, mixing, extraction, bottling and packaging on an exclusive basis. ETST believes such an arrangement would enable a consistent, marketable industrial hemp source. If completed, it would create more revenues for ETST, according to Nickolas S. Tabraue, president, director and chairman of ETST (http://ibn.fm/ghbac).
ETST is a biotech company based in Doral, Florida, marketing and developing CBD products for the pharmaceutical and nutraceutical fields. The company is focused on the cannabidiol, pharmaceutical, and nutraceutical sectors, as well as the development, through subsidiaries, of medical devices and research. ETST’s goal is to become a world leader in the CBD space.
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
